RANI Rani Therapeutics Holdings, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1856725 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY448.7%
TTM net income YoY-14.6%
TTM EPS YoY90.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-530.5%
Net margin-493.0%
FCF margin-352.7%
EBITDA margin-520.6%
Returns
ROE-248.6%
ROA-103.6%
ROIC (approx.)-173.1%
Asset turnover0.21x
Leverage & solvency
Liabilities / assets21.3%
Debt / equity0.00x
Current ratio5.26x
Interest coverage-71.86x
Cash quality & payout
Operating cash flow / net income0.71x
Accruals ratio-30.2%
Payout ratio—
Capex / revenue3.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $1.63M | $1.03M |
| R&D expense | $20.20M | $26.68M |
| SG&A expense | $19.74M | $23.95M |
| Operating income | -$38.31M | -$53.31M |
| Interest expense | $2.89M | $5.03M |
| Income tax | $0 | $0 |
| Net income | -$29.67M | -$30.02M |
| EBITDA | -$37.41M | -$52.29M |
| EPS (basic) | -0.45 | -1.05 |
| EPS (diluted) | -0.45 | -1.05 |
| Weighted avg. shares (diluted) | 66,138 | 28,476 |
| Balance sheet | ||
| Cash & equivalents | $18.62M | $4.26M |
| Receivables | $2.04M | $0 |
| Current assets | $53.32M | $29.74M |
| PP&E, net | $736,000 | $1.55M |
| Total assets | $58.62M | $36.63M |
| Current liabilities | $12.67M | $19.89M |
| Short-term debt | $0 | $15.00M |
| Long-term debt | $0 | $9.61M |
| Total debt | $0 | $24.61M |
| Total liabilities | $17.11M | $33.14M |
| Shareholders' equity | $33.01M | $1.99M |
| Net debt | -$18.62M | $20.35M |
| Cash flow statement | ||
| Operating cash flow | -$18.71M | -$35.50M |
| Capital expenditure | $88,000 | $268,000 |
| Free cash flow | -$18.80M | -$35.76M |
| Investing cash flow | -$7.03M | $19.81M |
| Financing cash flow | $40.30M | $13.59M |
| Depreciation & amortization | $900,000 | $1.03M |
| Stock-based compensation | $11.80M | $16.03M |
Free plan shows the latest 2 periods; Pro shows all 6 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.